Arabic Arabic English English French French German German
dark

ORYZON Presents Safety and Efficacy Data of Vafidemstat From the Phase II ESCAPE Trial in Severe COVID-19 Patients at ECCMID-2021

Oryzon Genomics, S.A. presented today preliminary data from the Phase II trial ESCAPE on vafidemstat’s ability to reduce the inflammatory response in COVID-19 patients. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Effect of yoga and physiotherapy on pulmonary functions in children with Duchenne muscular dystrophy.

Next Post

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

Related Posts
Total
0
Share